For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology.
Jul 9, 2026
0
3
The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and network meta-analysis published online July 2 ...
Jul 7, 2025
0
16
The U.S. Food and Drug Administration has approved UCB's Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa.
Nov 26, 2024
0
28
For patients with hidradenitis suppurativa (HS), bimekizumab is safe and efficacious over two years, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. ...
Oct 7, 2024
0
23
The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective ...
Sep 26, 2024
0
33
Bimekizumab is well tolerated and produces clinically meaningful responses in patients with hidradenitis suppurativa, according to a study published online May 22 in The Lancet.
May 30, 2024
0
20
Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are durable at four years, according to research presented at the annual meeting of ...
Mar 18, 2024
0
29
For patients with moderate-to-severe hidradenitis suppurativa (HS), bimekizumab shows promise in phase 3 trials, according to research presented at the annual meeting of the American Academy of Dermatology, held from March ...
Mar 29, 2023
0
41
